We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Magnisense and Indicia Announce Joint Testing Platform

By Labmedica staff writers
Posted on 27 Feb 2007
Magnisense (Rosny-sous-Bois, France), a developer of next generation immunoassays for human and animal diagnostics, food safety, and environmental protection, announced the availability of a platform for customers in the diagnostics industry to test systems based on Magnisense's Miatek technology. More...
The platform has been developed within a partnership with Indicia Biotechnology (Lyon, France), an immune technology specialist.

Miatek employs magnetic beads as markers, replacing the traditional enzymatic or fluorescent methods. Magnisense has already developed a portable reader that can identify and quantify accurately a biologic target using superparamagnetic beads as markers.

By linking up with Indicia, Magnisense opens the way for diagnostics or life science companies who wish to use Miatek for their own applications to develop quickly and economically tests which are specifically adapted to the desired markers and based on their own parameters.

Before or after acquiring a license from Magnisense, any of our customers can now rapidly judge the value of our technology thanks to our jointly-developed tests, said Luc Lenglet, CEO of Magnisense. Indicia brings two indispensable skills to the development of Miatek technology: immunoassays and reagents for the magnetic beads.

As well as extending our range of products and services, this partnership with Magnisense allows us to work on what we see as the future generation of immunoassays based on magnetic technology, said Stéphane Legastelois, chairman of Indicia Biotechnology. Companies interested in Magnisense's technology can now see quickly and easily for themselves the advantages such as the increased sensitivity and the quantification of fast testing.

Indicia Biotechnology offers a large range of technologies and assay formats including the enzyme-linked immunosorbant assay (ELISA), latex, lateral flow test, magnetic-beads immunoassay, multiplexing tests based on xMap technology, and antibody services. The whole organization is working towards quality standards in order to ensure that its development and production processes generate maximum performances and meet customer satisfaction.

Magnisense develops and markets a new generation of immunoassays for human and animal diagnostics, food safety, and environmental protection. These innovative immunoassays are based on magnetic bead markers, which deliver the accuracy of laboratory testing with the ease of use of rapid test methods currently on the market.


Related Links:
Magnisense
Indicia Biotechnology

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.